SCHD vs XLV: Quality Dividend Growth vs Healthcare Sector

Diversified quality dividend growth investing vs pure healthcare sector exposure. Which offers better defensive characteristics and growth potential in an aging population?

SCHD

SCHD

Schwab U.S. Dividend Equity ETF

3.27%
Dividend Yield
0.06%
Expense Ratio
11.2%
5-Year Return
104
Holdings

SCHD tracks the Dow Jones U.S. Dividend 100 Index, focusing on high dividend yield with rigorous quality screens. Requires 10+ years of dividend payments and screens for financial health metrics. Diversified across 11 sectors with healthcare as its largest allocation.

Quality Screens Low-Cost Dividend Growth Multi-Sector Value Focus
XLV

XLV

Health Care Select Sector SPDR Fund

1.52%
Dividend Yield
0.10%
Expense Ratio
13.5%
5-Year Return
65
Holdings

XLV tracks the Health Care Select Sector Index, providing pure exposure to healthcare companies within the S&P 500. Includes pharmaceuticals, biotechnology, healthcare equipment, healthcare services, and healthcare technology. 100% healthcare sector exposure.

Healthcare Sector Focus Defensive Demographic Tailwind Low-Cost

Key Metrics Comparison

Metric SCHD XLV Winner
Dividend Yield 3.27% 1.52% SCHD (+1.94%)
Expense Ratio 0.06% 0.10% SCHD (-0.04%)
5-Year Annual Return 11.2% 13.5% XLV (+2.3%)
Number of Holdings 104 65 SCHD
Assets Under Management $95.2B $41.8B SCHD
P/E Ratio 15.2 22.5 SCHD
Volatility (5-Year) 15.2% 16.8% SCHD (-1.6%)
Sector Concentration 11 Sectors 1 Sector Different Strategies

Performance Comparison

SCHD Performance

Strong total returns with significantly higher income. Quality screens provide defensive characteristics. Multi-sector diversification reduces single sector risk. Healthcare is largest sector at 18.5% but not dominant.

11.2%
5-Year Return
15.2%
Volatility
3.27%
Yield
0.85
Beta

XLV Performance

Higher total returns with lower income. Pure healthcare sector exposure benefits from demographic trends and innovation. Sector concentration provides focused growth but with sector-specific risks.

13.5%
5-Year Return
16.8%
Volatility
1.52%
Yield
0.75
Beta

Strategy Analysis

SCHD Approach

Multi-sector quality dividend growth:

  • Minimum 10 years of dividend payments
  • Dividend yield > 2.5% requirement
  • Cash flow to total debt > 50%
  • Return on equity > 15%
  • Market cap > $500 million
  • Diversified across 11 sectors
  • Healthcare is largest sector (18.5%)
  • Quality growth with income focus

XLV Approach

Pure healthcare sector exposure:

  • 100% healthcare sector focus
  • S&P 500 healthcare companies
  • Pharmaceuticals, biotech, equipment
  • Healthcare services and technology
  • Market-cap weighted within sector
  • Demographic tailwind exposure
  • Innovation and research focus
  • Defensive sector characteristics

Sector Concentration Analysis

SCHD offers multi-sector diversification (11 sectors, healthcare 18.5%) with quality screens, while XLV provides pure sector focus (100% healthcare). This represents the classic diversification vs concentration tradeoff.

SCHD Healthcare

18.5%
Largest Sector Exposure

SCHD Financials

15.2%
Second Largest

XLV Healthcare

100%
Pure Sector Focus

Number of Sectors

11 vs 1
Diversification Difference

Healthcare Subsector Breakdown (XLV)

XLV provides comprehensive exposure across all healthcare subsectors, with pharmaceuticals as the largest component. This diversified healthcare exposure includes both defensive (pharma) and growth (biotech) segments.

Pharmaceuticals

40% of XLV: Large-cap drug manufacturers

Examples: Johnson & Johnson, Pfizer, Merck

Characteristics: Defensive, stable dividends

Risk: Patent cliffs, regulation

Healthcare Equipment

22% of XLV: Medical devices and equipment

Examples: Abbott Labs, Medtronic, Boston Scientific

Characteristics: Innovation-driven growth

Risk: Regulatory approval cycles

Biotechnology

18% of XLV: Biotech research companies

Examples: Amgen, Gilead, Vertex

Characteristics: High growth potential

Risk: Clinical trial failures

Defensive Characteristics

Defensive Profile Comparison

Both SCHD and XLV offer defensive characteristics but through different mechanisms: SCHD through quality screens and dividend sustainability, XLV through healthcare sector's recession-resistant nature.

SCHD Beta

0.85
Lower Market Sensitivity

XLV Beta

0.75
Even Lower Sensitivity

2008 Performance

-35% vs -40%
XLV Outperformed S&P

2020 Performance

+10% vs -20%
XLV Positive in Crisis

Demographic Tailwinds (XLV Advantage)

Healthcare benefits from powerful demographic trends that provide secular growth tailwinds independent of economic cycles.

Aging Population

10,000 baby boomers turn 65 daily in US

Healthcare spending increases with age

Chronic disease prevalence rises with age

Multi-decade demographic trend

Innovation Cycle

Biotech breakthroughs (mRNA, gene therapy)

Medical device innovation (robotics, AI)

Pharmaceutical R&D continues to advance

Healthcare digitization accelerates

Economic Characteristics

Recession-resistant: Healthcare is necessity

Pricing power: Limited healthcare alternatives

Regulatory moats: FDA approvals create barriers

Global demand: Universal healthcare need

Income Analysis

SCHD Income Profile

Higher yield from multi-sector quality dividend payers. Focus on sustainable dividends from financially healthy companies across sectors. Strong dividend growth from quality companies.

Current Yield 3.27%
5-Year Dividend Growth 8.5%
Payout Ratio 45%
Healthcare Dividend 18.5%

XLV Income Profile

Lower yield from growth-focused healthcare sector. Many healthcare companies reinvest profits into R&D rather than dividends. Some pharmaceutical companies offer solid dividends but biotech typically does not.

Current Yield 1.52%
5-Year Dividend Growth 6.8%
Payout Ratio 35%
Pharma Dividend 40% of portfolio

Risk Analysis

SCHD Risk Profile

Multi-sector diversification reduces specific risks:

  • Sector concentration risk: Low (max 18.5% healthcare)
  • Regulatory risk: Spread across sectors
  • Dividend cut risk: Mitigated by quality screens
  • Interest rate sensitivity: Moderate
  • Economic cycle risk: Balanced across sectors
  • Company-specific risk: Diversified (104 holdings)
  • Quality risk: Addressed by financial screens
  • Overall risk: Lower due to diversification

XLV Risk Profile

Sector concentration creates specific risks:

  • Sector concentration risk: High (100% healthcare)
  • Regulatory risk: High (FDA, Medicare policies)
  • Patent cliff risk: Pharma specific
  • Clinical trial risk: Biotech specific
  • Political risk: Healthcare reform debates
  • Pricing pressure risk: Drug pricing legislation
  • Innovation risk: R&D failure rates
  • Overall risk: Higher due to concentration

Top Holdings Comparison

SCHD Top Holdings (Multi-Sector Quality)

Broadcom Inc. (Tech) 4.8%
AbbVie Inc. (Healthcare) 4.5%
Amgen Inc. (Healthcare) 4.3%
Home Depot Inc. (Consumer) 4.2%
Texas Instruments (Tech) 4.1%

Note: Healthcare represents 2 of top 5 holdings but only 18.5% of total portfolio

XLV Top Holdings (Pure Healthcare)

Johnson & Johnson 10.2%
UnitedHealth Group 9.8%
AbbVie Inc. 4.5%
Pfizer Inc. 4.3%
Merck & Co. 4.2%

Note: Top 10 holdings represent ~55% of portfolio, showing concentration in large-cap healthcare

Investment Recommendation

🎯 Choose SCHD If:

  • Higher current income is important (3.27% vs 1.52%)
  • Multi-sector diversification appeals to you
  • Lower costs matter (0.06% vs 0.10%)
  • Dividend growth is a priority (8.5% vs 6.8%)
  • You want quality screens and financial health filters
  • Sector concentration risk concerns you
  • You prefer balanced exposure across economic sectors
  • Lower volatility is desirable (15.2% vs 16.8%)

🏥 Choose XLV If:

  • Higher total returns matter (13.5% vs 11.2%)
  • You believe in healthcare demographic tailwinds
  • Defensive sector exposure appeals to you
  • You want pure healthcare sector exposure
  • Innovation and medical advances excite you
  • You can handle sector concentration risk
  • Lower current income is acceptable
  • You want recession-resistant characteristics

💡 Portfolio Construction Strategy

Most investors benefit from using SCHD as their core dividend holding (60-70% of dividend allocation) and adding XLV as a satellite healthcare position (10-20%). This provides quality dividend growth with targeted healthcare exposure. For healthcare-focused investors: 50% SCHD + 30% XLV + 20% other sectors. For maximum diversification: 80% SCHD + 20% XLV. Note that SCHD already has 18.5% healthcare exposure, so adding XLV increases healthcare concentration. Consider your overall portfolio healthcare exposure before adding XLV.

Back to All ETF compare

Which should you choose: SCHD vs XLV?

SCHD
Choose SCHD if you want a low-cost (0.06%) blend of an above-average ~3.27% yield and a strong dividend-growth record from screened, quality U.S. companies.
XLV
Choose XLV if you want a concentrated position in the health-care sector.
Bottom line: XLV is a concentrated bet on a single sector, while SCHD spreads risk across many sectors. Use XLV only as a satellite tilt around a diversified core like SCHD.